The global autoinjectors market is highly competitive, with a few major players dominating the market. These players are focused on developing innovative and user-friendly autoinjectors to cater to the growing demand for self-administration devices. Some of the key players in the market are:
- AbbVie Inc.: AbbVie is a research-based biopharmaceutical company that develops and markets a range of pharmaceuticals and medical devices. The company’s autoinjector portfolio includes products such as Humira, Skyrizi, and Rinvoq.
- Amgen Inc.: Amgen is a multinational biopharmaceutical company that develops and markets a range of innovative drugs and devices. The company’s autoinjector portfolio includes products such as Enbrel, Prolia, and Repatha.
- Eli Lilly and Company: Eli Lilly is a global healthcare company that develops and markets a range of pharmaceuticals and medical devices. The company’s autoinjector portfolio includes products such as Forteo, Humalog, and Trulicity.
- Mylan N.V.: Mylan is a global pharmaceutical company that develops and markets a range of drugs and devices. The company’s autoinjector portfolio includes products such as Adrenaclick, EpiPen, and Symjepi.
- Pfizer Inc.: Pfizer is a research-based pharmaceutical company that develops and markets a range of innovative drugs and devices. The company’s autoinjector portfolio includes products such as Xeljanz, Enbrel, and Toviaz.
Other players in the market include Teva Pharmaceutical Industries Ltd., Ypsomed AG, Becton, Dickinson and Company, Consort Medical plc, Gerresheimer AG, and SHL Group.
The major players in the market are focused on expanding their product portfolios through partnerships, collaborations, and acquisitions. For instance, in 2019, Mylan N.V. and Pfizer Inc. announced the formation of Viatris Inc., a new global healthcare company that would focus on expanding access to medicines and providing innovative healthcare solutions. Similarly, in 2019, AbbVie Inc. acquired Allergan plc to expand its product portfolio in the aesthetics and neuroscience segments.
The competitive landscape in the autoinjectors market is also characterized by technological advancements and product innovations. Manufacturers are investing in R&D to develop advanced autoinjectors that can improve patient outcomes and reduce the risk of errors. For instance, in 2018, Amgen Inc. launched its new autoinjector, SureClick, which features an audible click to confirm the dose has been delivered and a hidden needle to minimize the fear of injection.
In conclusion, the global autoinjectors market is highly competitive, with a few major players dominating the market. These players are focused on expanding their product portfolios and developing innovative and user-friendly autoinjectors to cater to the growing demand for self-administration devices. With increasing investment in R&D and strategic partnerships, the autoinjectors market is poised for significant growth in the future.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Everest Market Insights journalist was involved in the writing and production of this article.